These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Abciximab, a novel platelet-blocking drug: pharmacology and nursing implications. Mayer DM; Docktor WJ Crit Care Nurse; 1998 Apr; 18(2):29-37. PubMed ID: 9708118 [No Abstract] [Full Text] [Related]
12. GP IIb/IIIa inhibition in primary stenting: 'do it early, make it easy'. Montalescot G Eur Heart J; 2002 Feb; 23(4):259-60. PubMed ID: 11812056 [No Abstract] [Full Text] [Related]
13. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101 [TBL] [Abstract][Full Text] [Related]
14. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Bonizzoni E; Topol EJ; Chiariello M J Am Coll Cardiol; 2006 Feb; 47(3):685-6. PubMed ID: 16458158 [No Abstract] [Full Text] [Related]
16. On the use of abciximab in percutaneous coronary intervention. Iversen AZ Dan Med Bull; 2011 Aug; 58(8):B4312. PubMed ID: 21827726 [No Abstract] [Full Text] [Related]
17. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519 [TBL] [Abstract][Full Text] [Related]
18. [MULTISTRATEGY and FATA: merits, limits and troubles of no profit clinical trials in acute myocardial infarction]. Savonitto S G Ital Cardiol (Rome); 2009 Jun; 10(6):364-5. PubMed ID: 19603607 [No Abstract] [Full Text] [Related]
19. Regimen lowers rate of coronary events in diabetes. Husten L Lancet; 1998 Aug; 352(9129):711. PubMed ID: 9728999 [No Abstract] [Full Text] [Related]
20. CD40 ligand--assessing risk instead of damage? Freedman JE N Engl J Med; 2003 Mar; 348(12):1163-5. PubMed ID: 12646674 [No Abstract] [Full Text] [Related] [Next] [New Search]